AI-Designed Drug Rentosertib Shows Patients' Biological Age Drop of Up to 6 Years
xiaohu · x · 2026-09-09
Insilico Medicine published an exploratory study in Nature Biotechnology showing its generative-AI-designed drug rentosertib may reverse "biological age."
- Originally developed for idiopathic pulmonary fibrosis (IPF); prior 42-patient trial already improved lung function.
- Six independent AI aging clocks (Harvard, Oxford, Beijing, Insilico) consistently judged treated patients younger than placebo: on average 3-4 years younger at week 4, up to 6 years.
- Strict numbers: 71 patients in the Phase IIa trial, 42 in the proteomics substudy; 21 of 54 comparisons reached exploratory significance; 2.71-3.46 years is the 60mg QD group's placebo-adjusted drop at week 4.
- AI role: PandaOmics for target discovery, Chemistry42 for de novo molecule generation; TNIK identified as a dual fibrosis/aging target; 18 months from target to preclinical candidate.
- A Phase III registration trial for IPF has launched, planning to enroll 320 patients across 47 Chinese centers.
Related event: AI-Designed IPF Drug Rentosertib Shows Biological Age Reversal in Trial(18 posts)→
More from Research
- Qwen3.8-Flash-Next's open 180B weights hailed as a model organism for backdoor research — jd_pressman · 2026-10-27
- Latent-Foresight: world models that learn to predict their own future — abursuc · 2026-10-27
- UK AISI papers: no good safeguards yet against misuse of biological AI tools — davidmanheim · 2026-10-27
- CMU's XYBench: LLMs answer queries literally and reinforce user misconceptions — valentina__py · 2026-10-27
- arXiv advice from T. Dietterich: wrong primary category will almost surely get your paper on hold — tdietterich · 2026-10-27
- arXiv has 4,000+ papers on hold amid submission surge; moderator shares how to avoid it — tdietterich · 2026-10-27